Letters to the Editor

Profound and sustained response with next generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Department of Pediatric Oncology and Hematology, Bordeaux University hospital, Bordeaux
Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital- APHP, Paris
Department of Pediatric Hematology, Robert Debré Hospital- APHP, Paris
Department of Pediatric Oncology and Hematology, Besançon University Hospital, Besançon
Department of Pediatric Oncology and Hematology, Saint-Denis de la Réunion University Hospital
Department of Pediatric Hematology, Lille University Hospital, Lille
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Haematologica Early view May 19, 2022 https://doi.org/10.3324/haematol.2021.280081